292 related articles for article (PubMed ID: 28965205)
1. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?
Fujitani K; Kurokawa Y; Takeno A; Endoh S; Ohmori T; Fujita J; Yamasaki M; Takiguchi S; Mori M; Doki Y;
Gastric Cancer; 2018 May; 21(3):446-452. PubMed ID: 28965205
[TBL] [Abstract][Full Text] [Related]
2. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
Kim SG; Hwang SH
World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
[TBL] [Abstract][Full Text] [Related]
3. Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery.
Kaito A; Kinoshita T; Shitara K; Shibasaki H; Nishida T
Eur J Surg Oncol; 2017 Apr; 43(4):801-807. PubMed ID: 28187877
[TBL] [Abstract][Full Text] [Related]
4. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
5. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset.
Nakanishi K; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Gastric Cancer; 2019 Nov; 22(6):1215-1225. PubMed ID: 30955110
[TBL] [Abstract][Full Text] [Related]
6. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
Fukuchi M; Ishiguro T; Ogata K; Suzuki O; Kumagai Y; Ishibashi K; Ishida H; Kuwano H; Mochiki E
Ann Surg Oncol; 2015 Oct; 22(11):3618-24. PubMed ID: 25663597
[TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
9. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Yamaguchi T; Takashima A; Nagashima K; Makuuchi R; Aizawa M; Ohashi M; Tashiro K; Yamada T; Kinoshita T; Hata H; Kawachi Y; Kawabata R; Tsuji T; Hihara J; Sakamoto T; Fukagawa T; Katai H; Higuchi K; Boku N
Ann Surg Oncol; 2020 Jan; 27(1):284-292. PubMed ID: 31535301
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
Mita K; Ito H; Ota E; Takahashi K; Hashimoto M; Asakawa H; Hayashi T; Fujino K
Anticancer Res; 2017 Mar; 37(3):1329-1333. PubMed ID: 28314299
[TBL] [Abstract][Full Text] [Related]
12. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
[TBL] [Abstract][Full Text] [Related]
13. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
14. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
15. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
[TBL] [Abstract][Full Text] [Related]
18. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Zhang Q; Qian Y; Yin Y
Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
